Fibroblast Growth Factor 2-engaged cell spheroid for stem cell therapy: role of Interleukin 8 in the immune-modulatory effectiveness in the critical limb ischemia model.
Kim E., Joo Y., Kim JW., Kim SH.
Animal Study on Peripheral Artery Disease, Immune Modulation, published in Stem Cells Transl Med (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cells Transl Med (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41235768
- PMCID
- PMC12616473
- DOI
- 10.1093/stcltm/szaf051
Abstract (original English)
Background Stem cell therapy has emerged as a promising approach for treating critical limb ischemia (CLI), a condition caused by atherosclerosis that results in reduced blood flow and limb necrosis. However, the underlying therapeutic mechanisms involving factors secreted from stem cells are still in the early stages of exploration. This study focuses on investigating the tissue regenerative effects of interleukin-8 (IL8) secreted from cell spheroids. Methods Human adipose-derived stem cells (hASCs) were cultured on FGF2-tethered surfaces to form spheroid (FECS-Ad). A murine CLI model was established through femoral artery dissection, followed by the injection of various treatments, including PBS, hASC, FECS-Ad, IL8-silenced FECS-Ad, and recombinant IL8. Results Comparative analyses revealed that FECS-Ad injection resulted in a higher percentage of salvaged limbs, but these effects were attenuated when IL8 was silenced in FECS-Ad. Immunofluorescence staining, flow cytometry analysis and RT-qPCR of M1 and M2 macrophage markers demonstrated that IL8 has the ability to polarize macrophages to M2 type. Notably, FECS-Ad injection reduced apoptotic markers (caspase 8 and TUNEL) in ischemic tissues, whereas IL8 knockdown in FECS-Ad increased the proportion of apoptotic cells. FECS-Ad injected tissues showed larger regenerating muscle fibers with centrally located nuclei. Knockdown of
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Cellular therapy for the peripheral arterial disease treatment: Protocol for a systematic review and meta-analysis
Meta-analysis on Peripheral Artery Disease, published in PLoS One (2025) — summary generated from the PubMed abstract.
- 2025
PLoS One1 citations - Level ASystematic ReviewPubMed
The Efficacy of Stem Cells in Wound Healing: A Systematic Review.
Systematic Review on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
- 2024
Int J Mol Sci60 citations - Level AMeta-analysisEurope PMC
The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-An
Meta-analysis on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in J Clin Med (2024) — summary generated from the PubMed abstract.
- 2024
J Clin Med2 citations - Level ASystematic ReviewEurope PMC
A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia
Systematic Review on Peripheral Artery Disease, published in J Vasc Surg (2022) — summary generated from the PubMed abstract.
- 2022
J Vasc Surg23 citations - Level AMeta-analysisEurope PMC
Autologous Stem Cell Therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials
Meta-analysis with a reported sample of 1096 on Peripheral Artery Disease, Chronic Wound, published in Cells (2021) — summary generated from the PubMed abstract.
- 2021
- n = 1096
Cells19 citations - Level ARandomized Controlled TrialPubMed
Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF).
Randomized Controlled Trial with a reported sample of 114 on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.
- 2019
- n = 114
Stem Cell Res Ther57 citations